Research programme: PPAR delta agonists - sanofi-aventis

Drug Profile

Research programme: PPAR delta agonists - sanofi-aventis

Latest Information Update: 13 Mar 2009

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Hyperlipidaemia; Type 2 diabetes mellitus

Most Recent Events

  • 13 Mar 2009 Preclinical development ongoing
  • 22 Apr 2008 Preclinical development is ongoing
  • 24 Feb 2006 Preclinical trials in Type-2 diabetes mellitus in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top